A new education initiative aims to expand awareness of DBS and empower people with Parkinson’s to make informed decisions ...

The Michael J. Fox Foundation provides info on stem cell clinical trials for Parkinson’s and how to find available studies ...

We’re thrilled to be back for another year at Carson Beach! Whether you walk, run, volunteer, or cheer from the sidelines, your participation helps fuel progress and brings us closer to a cure.

Our experts discuss sexual changes in men and women with Parkinson's, how the disease and its impact affects intimate relationships, and what strategies and treatments can help. Register to watch on ...

Lacing up with Team Fox for an endurance event is simple. From London to Chicago to Tanzania, there is an event for our most adventurous athletes. Once you have decided what event you are interested ...

Donna Krenicki believes in momentum. Whether she’s hiking, golfing or spending the day with her young grandchildren (five under the age of 5), movement has always been central to her life. It’s how ...

Five takeaways on progress altering the Parkinson’s therapeutic landscape, from day two of The Michael J. Fox Foundation’s ...

New paper in The Lancet Neurology confirms that a key Parkinson’s pathology can now be identified by examining spinal fluid from living patients Test validated in the gold-standard Parkinson’s ...

The U.S. Food and Drug Administration (FDA) has approved tavapadon, a once-daily oral medication for the treatment of motor symptoms of Parkinson’s disease. Tavapadon, which will be sold under the ...

As part of The Michael J. Fox Foundation’s goal to support the development of new and better Parkinson’s treatments, we are regularly assessing and tracking the drug development pipeline. Five areas ...

The maker of prasinezumab announced this week that the drug is moving into the critical, Phase III stage of clinical trials. If successful, the trial’s findings ultimately could be used to request ...

The U.S. Food and Drug Administration (FDA) has approved a new, long-acting oral formulation for the treatment of Parkinson's disease. Developed by Amneal Pharmaceuticals, Crexont aims to offer ...